workers treated some sick patients by injecting them with plasma-the translucent part of this blood-taken from individuals who had survived the . In the absence of an approved drug to treat patients, the hope was that protective proteins in the donor plasma would help recipients fight the disease and recover.A biotech company wants to use this same approach to treat a variety of infectious diseases, with one key difference: cows, not humans, will be the plasma donors.SAB Biotherapeutics of South dakota has genetically engineered cattle to produce large quantities of human antibodies-proteins which help remove harmful foreign pathogens from the body-in an immediate fashion that could be employed to treat patients having difficulties with infectious diseases like Middle East respiratory syndrome (MERS), Ebola, and influenza. Society Health Organization recently recognized the company’s approach among six promising new technology platforms that could help respond to disease outbreaks worldwide.
No comments:
Post a Comment